Fig. 1

INI-43 pre-treatment significantly enhances cisplatin sensitivity in cervical cancer cell lines HeLa and SiHa. a Cisplatin IC₅₀ values in cervical cancer cell lines HeLa, CaSki, SiHa and C33A pre-treated with 2.5 μM and 5 μM INI-43 for 2 h, compared to control cells receiving no pre-treatment. Results shown are the mean IC₅₀ value ± SEM of three independent experiments (n = 6). b MTT cell proliferation assay 48 h post-treatment, showing increased cisplatin sensitivity in HeLa, CaSki and SiHa cells after pre-treatment with 5 μM INI-43. c Western blot analysis showing enhanced PARP cleavage in INI-43 and cisplatin combination treated HeLa and SiHa cells. GAPDH was used as a loading control, and quantification via densitometry is shown. The full-length blots are shown in Supplementary Fig. 2. d Caspase-3/7 activity in HeLa and SiHa cells was significantly enhanced upon INI-43 and cisplatin combination treatment, compared to cisplatin single treatment. In all cases, results shown are the mean ± SEM of experiments performed in triplicate and repeated three independent times (*p < 0.05)